Deletion of Mitochondrial Anchoring Protects Dysmyelinating Shiverer: Implications for Progressive MS

The demyelinating disease multiple sclerosis (MS) has an early inflammatory phase followed by an incurable progressive phase with subdued inflammation and poorly understood neurodegenerative mechanism. In this study, we identified various parallelisms between progressive MS and the dysmyelinating mouse model Shiverer and then genetically deleted a major neuron-specific mitochondrial anchoring protein Syntaphilin (SNPH) from the mouse. Prevailing evidence suggests that deletion of SNPH is harmful in demyelination. Surprisingly, SNPH deletion produces striking benefits in the Shiverer by prolonging survival, reducing cerebellar damage, suppressing oxidative stress, and improving mitochondrial health. In contrast, SNPH deletion does not benefit clinical symptoms in experimental autoimmune encephalomyelitis (EAE), a model for early-phase MS. We propose that deleting mitochondrial anchoring is a novel, specific treatment for progressive MS.

[1]  T. Schwarz,et al.  Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin , 2014, The Journal of cell biology.

[2]  Nobuhiko Ohno,et al.  Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons , 2014, Proceedings of the National Academy of Sciences.

[3]  Z. Sheng,et al.  Mitochondrial trafficking and anchoring in neurons: New insight and implications , 2014, The Journal of cell biology.

[4]  H. Lassmann,et al.  Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. , 2014, Trends in molecular medicine.

[5]  M. Mańczak,et al.  MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. , 2013, Biochimica et biophysica acta.

[6]  Ricarda Diem,et al.  Neurological deficits caused by tissue hypoxia in neuroinflammatory disease , 2013, Annals of neurology.

[7]  P. Stys.  Pathoetiology of multiple sclerosis: are we barking up the wrong tree? , 2013, F1000prime reports.

[8]  Hans Lassmann,et al.  Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.

[9]  P. Stys,et al.  Will the real multiple sclerosis please stand up? , 2012, Nature Reviews Neuroscience.

[10]  P. Reddy,et al.  Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage , 2012, The Journal of cell biology.

[11]  D. Bourdette,et al.  Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis , 2012, The European journal of neuroscience.

[12]  S. Dib-Hajj,et al.  A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis , 2012, Annals of neurology.

[13]  J. Geurts,et al.  Gray matter imaging in multiple sclerosis: what have we learned? , 2011, BMC neurology.

[14]  D. Turnbull,et al.  Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. , 2011, Brain : a journal of neurology.

[15]  H. Lassmann,et al.  Oxidative damage in multiple sclerosis lesions , 2011, Brain : a journal of neurology.

[16]  Richard Reynolds,et al.  Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis , 2011, Annals of neurology.

[17]  N. Oesingmann,et al.  Progressive multiple sclerosis and gray matter pathology: an MRI perspective. , 2011, The Mount Sinai journal of medicine, New York.

[18]  O. Ciccarelli,et al.  Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions , 2010, The Lancet Neurology.

[19]  A. Cross,et al.  Dysmyelinated axons in shiverer mice are highly vulnerable to α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-mediated toxicity , 2010, Brain Research.

[20]  Arthur W. Toga,et al.  Purkinje cell loss in experimental autoimmune encephalomyelitis , 2009, NeuroImage.

[21]  H. Weiner,et al.  Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. , 2008, The Journal of clinical investigation.

[22]  Cuiling Li,et al.  Docking of Axonal Mitochondria by Syntaphilin Controls Their Mobility and Affects Short-Term Facilitation , 2008, Cell.

[23]  D. Bourdette,et al.  Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis , 2007, Proceedings of the National Academy of Sciences.

[24]  D. Turnbull,et al.  Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the Shiverer mouse , 2006, Journal of neuroscience research.

[25]  S. Kuroda,et al.  Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia , 2004, Brain Research.

[26]  H. Lassmann,et al.  Comparison of myelin, axon, lipid, and immunopathology in the central nervous system of differentially myelin-compromised mutant mice: a morphological and biochemical study , 2004, Molecular and Cellular Neuroscience.

[27]  R. Chen,et al.  Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation , 2004, Circulation.

[28]  L. Dugan,et al.  Superoxide stress identifies neurons at risk in a model of ataxia‐telangiectasia , 2001, Annals of neurology.

[29]  V. Scheuss,et al.  Syntaphilin A Syntaxin-1 Clamp that Controls SNARE Assembly , 2000, Neuron.

[30]  K. Nave,et al.  Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. , 1998, Science.

[31]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[32]  R. Swingler,et al.  The morbidity of multiple sclerosis. , 1992, The Quarterly journal of medicine.

[33]  S. Molineaux,et al.  Recombination within the myelin basic protein gene created the dysmyelinating shiverer mouse mutation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Hood,et al.  Characterization of cloned cDNA representing rat myelin basic protein: Absence of expression in brain of shiverer mutant mice , 1983, Cell.

[35]  Yasuzo Tsukada,et al.  Fine structure of the central myelin sheath in the myelin deficient mutant Shiverer mouse, with special reference to the pattern of myelin formation by oligodendroglia , 1981, Brain Research.

[36]  P. Hanson,et al.  Explorer Mitochondrial changes within axons in multiple sclerosis , 2016 .

[37]  E. Bonilla,et al.  Optical imaging techniques (histochemical, immunohistochemical, and in situ hybridization staining methods) to visualize mitochondria. , 2001, Methods in cell biology.